Your new experience awaits. Try the new design now and help us make it even better

RETRACTION article

Front. Cell Dev. Biol., 06 October 2025

Sec. Molecular and Cellular Pathology

Volume 13 - 2025 | https://doi.org/10.3389/fcell.2025.1712881

Retraction: miR-335 targets LRRK2 and mitigates inflammation in Parkinson’s disease

This article is a retraction of:

  1. RETRACTED: miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinson’s Disease

    1. Read original article
Frontiers Editorial Office Frontiers Editorial Office*

A Retraction of the Original Research article
miR-335 targets LRRK2 and mitigates inflammation in Parkinson’s disease

by Oliveira SR, Dionísio PA, Gaspar MM, Correia Guedes L, Coelho M, Rosa MM, Ferreira JJ, Amaral JD and Rodrigues CMP (2021). Front. Cell Dev. Biol. 9:661461. doi: 10.3389/fcell.2021.661461

The journal retracts the 15 June 2021 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies.

This retraction was approved by the Chief Editors of Frontiers in Cell and Developmental Biology and the Chief Executive Editor of Frontiers. The authors received a communication regarding the retraction and had a chance to respond. This communication has been recorded by the publisher.

Frontiers would like to thank the concerned reader who contacted us regarding the published article.

Citation: Frontiers Editorial Office (2025) Retraction: miR-335 targets LRRK2 and mitigates inflammation in Parkinson’s disease. Front. Cell Dev. Biol. 13:1712881. doi: 10.3389/fcell.2025.1712881

Received: 25 September 2025; Accepted: 25 September 2025;
Published: 06 October 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office, cmVzZWFyY2guaW50ZWdyaXR5QGZyb250aWVyc2luLm9yZw==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.